Comparative Pharmacology
Head-to-head clinical analysis: ARANELLE versus OGESTREL 0 5 50 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANELLE versus OGESTREL 0 5 50 28.
ARANELLE vs OGESTREL 0.5/50-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial development.
One tablet (norethindrone 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (norgestrel 0.5 mg/ethinyl estradiol 50 mcg) orally once daily for 28-day cycle.
None Documented
None Documented
Terminal half-life 12-14 hours; steady-state achieved within 2-3 days; clinical context supports once-daily dosing
Norgestrel: ~45 hours (range 24-56 h) enabling once-daily dosing; Ethinyl estradiol: ~17 hours (range 10-27 h).
Renal 50-60% as metabolites (sulfate and glucuronide conjugates), fecal 30-40%, biliary 10%
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norgestrel and ethinyl estradiol); Fecal: 30-40% via biliary elimination; Unchanged drug: <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive